Latest News in the pharma Industry
Research & Development
Metacrine collaborates on development of FGF1 variants for glucose lowering and improving insulin sensitivity
16 Aug 2017
Novo Nordisk will have an option to license the FGF1 program upon achievement of certain research milestones.
Read more
Regeneron to discontinue development of suptavumab for respiratory syncytial virus
14 Aug 2017
Phase III study fails to meet its primary endpoint.
Read more
Ionis to go it alone with Inotersen and IONIS-FB-L Rx after GSK decline
14 Aug 2017
Inotersen on track for marketing authorization filings this year.
Read more
Fortress Biotech forms new subsidiary, Aevitas Therapeutics
14 Aug 2017
Subsidiary to develop novel AAV gene therapy treatments for complement-mediated.
Read more
Kalytera submits Phase II study protocol to IRBs for cannabidiol in the prevention of GvHD
14 Aug 2017
The Phase II study is designed to generate the pharmacokinetic and safety data, at multiple dose levels, that will be required by the FDA.
Read more
FDA removes clinical hold on CEL-SCI’s Phase III head & neck cancer trial
14 Aug 2017
The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.
Read more
Experimental treatment for Niemann-Pick disease type C1 appears safe, effective
13 Aug 2017
NIH-led clinical trial suggests that drug slows progression of rare neurological disease.
Read more
Major progress in next generation medicines initiative
10 Aug 2017
Juniper Pharma Services now has CrystecPharma’s supercritical fluid technology platform on-site.
Read more
NCI study identifies essential genes for cancer immunotherapy
7 Aug 2017
This knowledge could speed the development of a new category of drugs.
Read more
AbbVie's Mavyret receives FDA approval for the treatment of chronic hepatitis C
6 Aug 2017
FDA approval is supported by an overall 98% cure rate in patients who received the recommended duration of treatment .
Read more
IDT launches first Cas9 enzyme that drastically reduces CRISPR off-target effects without significant loss of on-target activity
3 Aug 2017
The launch represents a major step towards therapeutic use of CRISPR.
Read more
BMS receives FDA approval for Opdivo Injection for metastatic colorectal cancer
3 Aug 2017
Approval based on CheckMate -142, in which Opdivo demonstrated an objective response rate of 28% among patients who received prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Read more